![Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium](https://www.finanznachrichten.de/chart-puma-biotechnology-inc-aktie-intraday-tradegate.png)
Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
![Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga](https://www.benzinga.com/files/images/story/2012/aapharma_3098.png)
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
![Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal](https://d3evu7qlt2vui6.cloudfront.net/wp-content/uploads/2021/12/PG12_PUMA_HC_SECONDARY_1206_Alan_Auerbach.png)
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
![Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181263174/image_1181263174.jpg?io=getty-c-crop-4-3)
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
![The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo](https://s.yimg.com/ny/api/res/1.2/QsH6XzuE3O7AAEj6zp9p_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://cdn1.benzinga.com/files/imagecache/600x400xUP/images/story/2012/medications-257336_1920_52.jpg)
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
![Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2021/4/25/saupload_zys-A0tTqP8PWlrKLGfU8XarhV75bml0GYT6UZXNdTCeU2AaCXx_644abKUiyEdFCXTOTLutlWDqvkveyTHWK0PYMs5db5WuIcg_P_sz1aH9ATSAfg5L9AuFRgTc-G3-cE9vOVv7.png)
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal](http://media.bizj.us/view/img/4563671/fred-eshelman-2*750xx2220-2962-1780-0.jpg)
Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal
![Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News](https://cdn-news.warriortrading.com/wp-content/uploads/2017/07/19181628/PBYI.jpg)